Review highlights advancements in microneedle-mediated nanoparticle delivery, indicating significant potential for various diseases.
Microneedle-mediated nanoparticle delivery (MND) has emerged as a transformative approach in transdermal drug delivery because it integrates the benefits of nanoparticles, such as improving drug stability, targeted delivery, and controlled release, with the minimally invasive and patient-compliant characteristics of microneedles (MNs). These hybrid systems enable the delivery of multifunctional nanomedicines, presenting significant potential to revolutionize the prevention and treatment of a wide range of diseases. In addition, compared to conventional microinjections, the minimally invasive and patient-friendly nature of MNs results in reduced pain and discomfort for patients. This review highlights recent advancements in nanoparticle-integrated MN technology for treating cancer, immune disorders, skin diseases, pain management, and diabetes. The synergistic combination of MNs with nanocarriers, such as polymeric nanoparticles, liposomes, and metal-based nanostructures, to enable precise drug localization, control drug release, reduce systemic toxicity, and enhance therapeutic response is also reviewed, demonstrating how nanoparticle-loaded MNs may revolutionize non-invasive drug delivery as an efficient, painless, and patient-compliant formulation. Additionally, we discuss the challenges and future directions in optimizing these systems for clinical translation.
No takes yet. Share an insight, caveat, or question.
Akbari et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: